NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy

PartnershipPositive

AI Analysis

Summary

NewBiologix and Synastra announced a collaboration to advance recombinant AAV (rAAV) manufacturing for Duchenne gene therapy, combining Synastra's genomic engineering and gene therapy expertise with NewBiologix's cell engineering and manufacturing technologies.

Importance:5/10

Sentiment:

0.40

gene therapyAAV vectormanufacturingDuchenne muscular dystrophycollaboration

Related Companies

$TRAX

Read the original article

Published by GEN - Genetic Engineering & Biotech News on September 5, 2026 1:44 PM

Read Original